A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity
Long-term Extension Study of BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age
Sponsor: Allergan
Listed as NCT01852058, this PHASE3 trial focuses on Urinary Incontinence and remains completed. Sponsored by Allergan, it has been updated 14 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 9 earlier versions
-
Jan 2020 — Jun 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Nov 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE3
-
Oct 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE3
-
Jul 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Oct 2018 — Jul 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Feb 2017 — Sep 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Allergan
For direct contact, visit the study record on ClinicalTrials.gov .